Measuring HER-2 in breast cancer. Immunohistochemistry, FISH, or ELISA?

Measuring HER-2 is important for selecting optimal therapy and predicting prognosis in breast cancer patients. Current methods for evaluating HER-2 include measuring protein overexpression by immunohistochemistry (IHC), measuring gene copy number by fluorescent in situ hybridization (FISH), and measuring shed antigen in the serum by enzyme-linked immunosorbent assay (ELISA). This review compares these 3 methods and analyzes the current literature pertaining to this subject. In comparing IHC with FISH, the negative predictive value is excellent for commonly used commercial antibodies but the positive predictive value is highly variable. However, by considering only strongly staining cases as positive by IHC, the positive predictive value is markedly improved. ELISA is useful in the follow-up care of patients with breast cancer. An algorithm for using all 3 methods is presented.

[1]  J. Fletcher,et al.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.

[2]  W. Harrison,et al.  Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. , 2000, American journal of clinical pathology.

[3]  M. Gnant,et al.  Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  S. Pileri,et al.  Immunohistochemical expression of internal and external ErbB‐2 domains in invasive breast cancer , 1999, Breast Cancer Research and Treatment.

[5]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[6]  B. Lloveras,et al.  Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  D. Tenney,et al.  Automated assay for HER-2/neu in serum. , 2000, Clinical chemistry.

[8]  N. Sneige,et al.  HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.

[9]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Frenkel,et al.  Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. , 2001, American journal of clinical pathology.

[11]  S J Schnitt,et al.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Davison,et al.  Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications. , 1998, The American journal of pathology.

[13]  A. Freemont,et al.  Subtractive hybridization – genetic takeaways and the search for meaning , 2000, International journal of experimental pathology.

[14]  D. Larsimont,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. , 2000, American journal of clinical pathology.

[15]  A. Vincent-Salomon,et al.  Quantitative PCR analysis of c‐erb B‐2 (HER2/neu) gene amplification and comparison with p185HER2/neu protein expression in breast cancer drill biopsies , 1999, International journal of cancer.

[16]  D. Berry,et al.  Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  I. Bièche,et al.  Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer. , 2001, Archives of pathology & laboratory medicine.

[19]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[20]  R. Simon,et al.  Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use , 2000, Histopathology.

[21]  Takashi Suzuki,et al.  Chromogenic in situ hybridization analysis of HER‐2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin®) therapy , 2001, Pathology international.

[22]  E. Sasse.  Objective evaluation of data in screening for disease. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[23]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[24]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  M. Dowsett,et al.  Assessment of HER2 status in breast cancer: why, when and how? , 2000, European journal of cancer.

[27]  D. Slamon,et al.  Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy , 2004, Breast Cancer Research and Treatment.

[28]  A. Vincent-Salomon,et al.  Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma , 2000, Modern Pathology.

[29]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[30]  E. Frenkel,et al.  Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays , 2000, Journal of clinical pathology.

[31]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[32]  R. Zeillinger,et al.  Tissue expression and serum levels of HER-2/neu in patients with breast cancer. , 1997, Oncology.

[33]  D. Visscher,et al.  Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.

[34]  T. Grogan,et al.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[36]  D. Treré,et al.  c‐erbB‐2 over‐expression in amplified and non‐amplified breast carcinoma samples , 1999, International journal of cancer.

[37]  R. Ridolfi,et al.  HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.

[38]  D. Birnbaum,et al.  Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation , 1994, The Journal of pathology.

[39]  D. Chan,et al.  Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. , 2001, Anticancer research.

[40]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[42]  A. Ebert,et al.  Current use of HER2 tests. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  L. Melton,et al.  HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.